市場調查報告書
商品編碼
939018

病毒載體、質體DNA製造:全球市場的展望(2018年∼2027年)

Viral Vector & Plasmid DNA Manufacturing - Global Market Outlook (2018-2027)

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 179 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球病毒載體、質體DNA製造市場,2018年是3億2,160萬美金。該市場,預計在預測期間內以15.1%的年複合成長率成長,2027年達到11億7,824萬美元。促進市場成長的主要原因,是基因治療相關警戒心的高漲,及基因治療相關的R&D的資金籌措高等。但,基因治療的高費用是抑制市場成長的要素。

本報告提供全球病毒載體、質體DNA製造市場的相關調查,市場機會和趨勢,成長及阻礙因素,各媒介類型、工作流程、疾病、銷售管道、用途、最終用途、地區的市場分析,競爭情形,主要企業的簡介等的資訊。

目錄

第1章 摘要整理

第2章 簡介

第3章 市場趨勢分析

  • 簡介
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 威脅
  • 用途分析
  • 終端用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病的影響

第4章 波特的五力分析

第5章 全球市場:各媒介類型

  • 簡介
  • 病毒載體
  • 非病毒載體

第6章 全球市場:工作流程

  • 簡介
  • 下游處理
  • 上游產業處理

第7章 全球市場:各疾病

  • 簡介
  • 感染疾病
  • 癌症
  • 遺傳性疾病

第8章 全球市場:各銷售管道

  • 簡介
  • 直銷
  • 流通管道銷售

第9章 全球市場:各用途

  • 簡介
  • 疫苗
  • 反義、RNAi,及分子療法
  • 細胞療法
  • 癌症
  • 病毒感染
  • 基因治療
  • 遺傳性疾病
  • 病毒疫苗
  • 蛋白質表現研究
  • 製劑開發

第10章 全球市場:各終端用戶

  • 簡介
  • 製藥、生物醫藥品企業
  • 調查機關
  • 免疫療法
  • DNA疫苗
  • 醫院

第11章 全球市場: 各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第12章 主要發展

  • 契約,聯盟,合作,合資企業
  • 收購與合併
  • 新產品的銷售
  • 擴張
  • 其他主要策略

第13章 企業簡介

  • Lonza
  • Catapult
  • uniQure N.V.
  • FUJIFILM Diosynth Biotechnologies(Fujifilm 株式會社)
  • Kaneka Eurogentec S.A.(Kaneka Corporation)
  • Oxford Biomedica
  • Spark Therapeutics, Inc.
  • Cobrabiologics
  • Merck KGaA
  • Brammer Bio
  • Cell and Gene Therapy Catapult
  • FinVector Vision Therapies
  • MassBiologics
  • SIRION Biotech
  • Thermo Fisher Scientific
目錄

According to Stratistics MRC, the Global Viral Vector & Plasmid DNA Manufacturing market is accounted for $321.60 million in 2018 and is expected to reach $1,178.24 million by 2027 growing at a CAGR of 15.1% during the forecast period. Some of the factors such as raise in alertness regarding gene therapy and raise in funding for R&D performance pertaining to gene therapy are driving the growth of the market. However, high price linked with gene therapies is likely to hamper the market growth.

Viral Vector & Plasmid DNA are commodities of gene therapy, which are used for the dealing of a great number of diseases. The advantages of gene vaccines and therapy in excess of conventional vaccines and therapies include the capacity to bring a wide variety of immune response types. A number of clinical studies are being conducted on this market, which highlight the potential of gene therapy to deal with significant medical needs, and have initiated a surge of savings in drug expansion and commercialization of these therapies.

By vector type, plasmid DNA segment is likely to have a huge demand in the forecast period due to the clinical research applications in gene therapy and genetic vaccination. The command and therapeutic applications for plasmid DNA (pDNA) have fast grown and extended.

On the basis of geography, North America is estimated to have a huge demand owing to the growing investments in gene therapy commodities in the United States in recent years. In the United States, rigid support and patient encouragement have pressed rare illness clinical research to the centre stage.

Some of the key players in Viral Vector & Plasmid DNA Manufacturing Market include Lonza, Catapult, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec S.A., Oxford Biomedica, Spark Therapeutics, Inc., Cobrabiologics, Merck KGaA, Brammer Bio, Cell and Gene Therapy Catapult, FinVector Vision Therapies, MassBiologics, SIRION Biotech and Thermo Fisher Scientific.

Vector Types Covered:

  • Viral Vectors
  • Non-Viral Vectors

Workflows Covered:

  • Downstream Processing
  • Upstream Processing

Diseases Covered:

  • Infectious Diseases
  • Cancer
  • Genetic Disorders

Sales Channels Covered:

  • Direct Sales
  • Channel Sales

Applications Covered:

  • Vaccinology
  • Antisense & RNAi, & Molecular Therapy
  • Cell Therapy
  • Cancer
  • Viral Infections
  • Gene Therapy
  • Inherited Disorders
  • Viral Vaccines
  • Protein Expression Studies
  • Formulation Development

End Users Covered:

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • Immunotherapy
  • DNA Vaccines
  • Hospitals

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis, etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Vector & Plasmid DNA Manufacturing Market, By Vector Type

  • 5.1 Introduction
  • 5.2 Viral Vectors
    • 5.2.1 Lentiviral Vectors
    • 5.2.2 Adenoviral Vectors
    • 5.2.3 Retroviral Vectors
    • 5.2.4 Adeno-Associated Virus (AAV)
    • 5.2.5 Other Viral Vectors
      • 5.2.5.1 Simian Virus
      • 5.2.5.2 Alphavirus
      • 5.2.5.3 Herpes Simplex Virus
      • 5.2.5.4 Sendai Virus
      • 5.2.5.5 Foamy Virus
      • 5.2.5.6 Vaccinia Virus
  • 5.3 Non-Viral Vectors
    • 5.3.1 Plasmid DNA
    • 5.3.2 Liposomes, Lipoplexes and Polyplexes
    • 5.3.3 Oligonucleotides

6 Global Viral Vector & Plasmid DNA Manufacturing Market, By Workflow

  • 6.1 Introduction
  • 6.2 Downstream Processing
    • 6.2.1 Fill-Finish
    • 6.2.2 Purification
  • 6.3 Upstream Processing
    • 6.3.1 Vector Recovery/Harvesting
    • 6.3.2 Vector Amplification & Expansion

7 Global Viral Vector & Plasmid DNA Manufacturing Market, By Disease

  • 7.1 Introduction
  • 7.2 Infectious Diseases
  • 7.3 Cancer
  • 7.4 Genetic Disorders

8 Global Viral Vector & Plasmid DNA Manufacturing Market, By Sales Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Channel Sales

9 Global Viral Vector & Plasmid DNA Manufacturing Market, By Application

  • 9.1 Introduction
  • 9.2 Vaccinology
  • 9.3 Antisense & RNAi, & Molecular Therapy
  • 9.4 Cell Therapy
  • 9.5 Cancer
  • 9.6 Viral Infections
  • 9.7 Gene Therapy
  • 9.8 Inherited Disorders
  • 9.9 Viral Vaccines
  • 9.10 Protein Expression Studies
  • 9.11 Formulation Development

10 Global Viral Vector & Plasmid DNA Manufacturing Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical and Biopharmaceutical Companies
  • 10.3 Research Institutes
  • 10.4 Immunotherapy
  • 10.5 DNA Vaccines
  • 10.6 Hospitals

11 Global Viral Vector & Plasmid DNA Manufacturing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Lonza
  • 13.2 Catapult
  • 13.3 uniQure N.V.
  • 13.4 FUJIFILM Diosynth Biotechnologies
  • 13.5 Kaneka Eurogentec S.A.
  • 13.6 Oxford Biomedica
  • 13.7 Spark Therapeutics, Inc.
  • 13.8 Cobrabiologics
  • 13.9 Merck KGaA
  • 13.10 Brammer Bio
  • 13.11 Cell and Gene Therapy Catapult
  • 13.12 FinVector Vision Therapies
  • 13.13 MassBiologics
  • 13.14 SIRION Biotech
  • 13.15 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Region (2017-2027) ($MN)
  • Table 2 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Type (2017-2027) ($MN)
  • Table 3 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Vectors (2017-2027) ($MN)
  • Table 4 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Lentiviral Vectors (2017-2027) ($MN)
  • Table 5 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Adenoviral Vectors (2017-2027) ($MN)
  • Table 6 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Retroviral Vectors (2017-2027) ($MN)
  • Table 7 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Adeno-Associated Virus (AAV) (2017-2027) ($MN)
  • Table 8 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Other Viral Vectors (2017-2027) ($MN)
  • Table 9 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Non-Viral Vectors (2017-2027) ($MN)
  • Table 10 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Plasmid DNA (2017-2027) ($MN)
  • Table 11 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Liposomes, Lipoplexes and Polyplexes (2017-2027) ($MN)
  • Table 12 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Oligonucleotides (2017-2027) ($MN)
  • Table 13 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Workflow (2017-2027) ($MN)
  • Table 14 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Downstream Processing (2017-2027) ($MN)
  • Table 15 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Fill-Finish (2017-2027) ($MN)
  • Table 16 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Purification (2017-2027) ($MN)
  • Table 17 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Upstream Processing (2017-2027) ($MN)
  • Table 18 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Recovery/Harvesting (2017-2027) ($MN)
  • Table 19 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vector Amplification & Expansion (2017-2027) ($MN)
  • Table 20 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Disease (2017-2027) ($MN)
  • Table 21 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Infectious Diseases (2017-2027) ($MN)
  • Table 22 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cancer (2017-2027) ($MN)
  • Table 23 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Genetic Disorders (2017-2027) ($MN)
  • Table 24 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Sales Channel (2017-2027) ($MN)
  • Table 25 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Direct Sales (2017-2027) ($MN)
  • Table 26 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Channel Sales (2017-2027) ($MN)
  • Table 27 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Application (2017-2027) ($MN)
  • Table 28 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Vaccinology (2017-2027) ($MN)
  • Table 29 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Antisense & RNAi, & Molecular Therapy (2017-2027) ($MN)
  • Table 30 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cell Therapy (2017-2027) ($MN)
  • Table 31 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Cancer (2017-2027) ($MN)
  • Table 32 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Infections (2017-2027) ($MN)
  • Table 33 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Gene Therapy (2017-2027) ($MN)
  • Table 34 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Inherited Disorders (2017-2027) ($MN)
  • Table 35 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Viral Vaccines (2017-2027) ($MN)
  • Table 36 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Protein Expression Studies (2017-2027) ($MN)
  • Table 37 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Formulation Development (2017-2027) ($MN)
  • Table 38 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By End User (2017-2027) ($MN)
  • Table 39 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2017-2027) ($MN)
  • Table 40 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Research Institutes (2017-2027) ($MN)
  • Table 41 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Immunotherapy (2017-2027) ($MN)
  • Table 42 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By DNA Vaccines (2017-2027) ($MN)
  • Table 43 Global Viral Vector & Plasmid DNA Manufacturing Market Outlook, By Hospitals (2017-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.